Moberg Pharma AB (publ) logo

MOB - Moberg Pharma AB (publ) Share Price

SEK5.85 -0.0  -0.3%

Last Trade - 3:50pm

Micro Cap
Market Cap £10.9m
Enterprise Value £8.35m
Revenue £227k
Position in Universe 1546th / 1829
Unlock MOB Revenue
Relative Strength (%)
1m -1.05%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -54.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
334.3 439 4.55 15.6 50.5 50.5 -31.5%
-95.2 +80.8 -40.5
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, MobergPharma AB (publ) revenues totaled SEK50.5M. Net incomebefore extraordinary items totaled to SEK10.4M. Results arenot comparable due to year end change.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


MOB Revenue Unlock MOB Revenue

Net Income

MOB Net Income Unlock MOB Revenue

Normalised EPS

MOB Normalised EPS Unlock MOB Revenue

PE Ratio Range

MOB PE Ratio Range Unlock MOB Revenue

Dividend Yield Range

MOB Dividend Yield Range Unlock MOB Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
MOB EPS Forecasts Unlock MOB Revenue
Profile Summary

Moberg Pharma AB is a Sweden-based pharmaceutical company. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The Company collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. It is active in more than 35 countries, and operates, among others, through Alterna LLC. It also owns three Over-The-Counter (OTC) brands in the United States.

Last Annual December 31st, 2020
Last Interim September 30th, 2020
Public Since May 26, 2011
No. of Shareholders: n/a
No. of Employees: 12
Sector Healthcare
Industry Pharmaceuticals
Exchange OMX Nordic Exchange Stockholm
Shares in Issue 21,828,351
Free Float (0.0%)
Eligible for
MOB Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for MOB
Upcoming Events for MOB
Tuesday 11th May, 2021
Q1 2021 Moberg Pharma AB (publ) Earnings Release
Tuesday 11th May, 2021
Moberg Pharma AB (publ) at Redeye Investor Forum (Virtual)
Tuesday 18th May, 2021
Moberg Pharma AB (publ) Annual Shareholders Meeting
Wednesday 2nd June, 2021
Moberg Pharma AB (publ) at Redeye Growth Day
Tuesday 10th August, 2021
Q2 2021 Moberg Pharma AB (publ) Earnings Release
Frequently Asked Questions for Moberg Pharma AB (publ)
What is the Moberg Pharma AB (publ) share price?

As of 3:50pm, shares in Moberg Pharma AB (publ) are trading at SEK5.85, giving the company a market capitalisation of £10.9m. This share price information is delayed by 15 minutes.

How has the Moberg Pharma AB (publ) share price performed this year?

Shares in Moberg Pharma AB (publ) are currently trading at SEK5.85 and the price has moved by -48.91% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Moberg Pharma AB (publ) price has moved by -61.79% over the past year.

What are the analyst and broker recommendations for Moberg Pharma AB (publ)?

Of the analysts with advisory recommendations for Moberg Pharma AB (publ), there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Moberg Pharma AB (publ) is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Moberg Pharma AB (publ) next release its financial results?

Moberg Pharma AB (publ) is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Moberg Pharma AB (publ) dividend yield?

Moberg Pharma AB (publ) does not currently pay a dividend.

Does Moberg Pharma AB (publ) pay a dividend?

Moberg Pharma AB (publ) does not currently pay a dividend.

When does Moberg Pharma AB (publ) next pay dividends?

Moberg Pharma AB (publ) does not currently pay a dividend.

How do I buy Moberg Pharma AB (publ) shares?

To buy shares in Moberg Pharma AB (publ) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Moberg Pharma AB (publ)?

Shares in Moberg Pharma AB (publ) are currently trading at SEK5.85, giving the company a market capitalisation of £10.9m.

Where are Moberg Pharma AB (publ) shares listed? Where are Moberg Pharma AB (publ) shares listed?

Here are the trading details for Moberg Pharma AB (publ):

Country of listing: Sweden
Exchange: STO
Ticker Symbol: MOB
What kind of share is Moberg Pharma AB (publ)?

Based on an overall assessment of its quality, value and momentum, Moberg Pharma AB (publ) is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Moberg Pharma AB (publ) share price forecast 2021?

Shares in Moberg Pharma AB (publ) are currently priced at SEK5.85. At that level they are trading at 1.13% discount to the analyst consensus target price of 0.00.

Analysts covering Moberg Pharma AB (publ) currently have a consensus Earnings Per Share (EPS) forecast of -0.94 for the next financial year.

How can I tell whether the Moberg Pharma AB (publ) share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Moberg Pharma AB (publ). Over the past six months, the relative strength of its shares against the market has been -44.22%. At the current price of SEK5.85, shares in Moberg Pharma AB (publ) are trading at -23.95% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Moberg Pharma AB (publ) PE Ratio?

We were not able to find PE ratio data for Moberg Pharma AB (publ).

Who are the key directors of Moberg Pharma AB (publ)?

Moberg Pharma AB (publ)'s management team is headed by:

Peter Wolpert - CHM
Anna Ljung - CEO
Fredrik Granstrom - IND
Mattias Klintemar - IND
Torbjorn Warnheim - DCE
Mark Beveridge - VFN
Annica Magnusson - OTH
Andrew Hochman - IND
Cindy Wong - OTH
Who are the major shareholders of Moberg Pharma AB (publ)?

Here are the top five shareholders of Moberg Pharma AB (publ) based on the size of their shareholding:

Östersjöstiftelsen Corporation
Percentage owned: 9.88% (4.41m shares)
Avanza Bank Holding AB Corporation
Percentage owned: 9.04% (4.03m shares)
Banque Cantonale Vaudoise Bank and Trust
Percentage owned: 4.19% (1.87m shares)
Nordnet Pensionsforsakring AB Corporation
Percentage owned: 4.05% (1.81m shares)
Medical Strategy GmbH Investment Advisor
Percentage owned: 2.05% (914k shares)
Similar to MOB
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.